Q4 2025 total revenue was $85.8 million (+42.8% YoY), led by Recorlev $45.3 million (+100.5%), Gvoke $24.6 million (+5.9%), and Keveyis $12.8 million (+15.1%). Full-year 2025 total revenue was $291.8 million (+43.7% YoY): Recorlev $139.3 million (+116.7%), Gvoke $94.1 million (+13.6%), Keveyis $47.6 million (-3.8%). Q4 net income was $11.1 million versus a net loss of $5.1 million in Q4 2024; full-year 2025 net income was $0.6 million versus a net loss of $54.8 million in 2024. Adjusted EBITDA was $25.1 million in Q4 2025 and $59.4 million for full-year 2025 (up from $8.3 million and $1.2 million in the prior-year periods). Full-year 2025 operating costs: COGS $42.6 million (+16%), R&D $31.2 million (+22%, driven by XP-8121), SG&A $182.4 million (+12%). Balance sheet at 12/31/2025: cash $111.0 million (up from $71.6 million), total debt ~$235.4 million (including $15.1 million current portion), stockholders’ equity turned positive at $13.7 million. Total shares outstanding were 172,431,290 as of February 27, 2026. 2026 guidance: total revenue $375–$390 million (midpoint ≈ +31% YoY), modest gross margin improvement, R&D up ≈ $25 million (XP-8121 Phase 3), SG&A up ≈ $45 million (Recorlev investments), Adjusted EBITDA to increase versus 2025.